

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3777013

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ADAGIO PHARMACEUTICALS LTD.	02/23/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CYNAPSUS THERAPEUTICS, INC.
<b>Street Address:</b>	828 RICHMOND STREET, W
<b>City:</b>	TORONTO
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	M6J 1C9
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14963910
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)428-7045
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617) 428-0200
<b>Email:</b>	patentadministrator@clarkelbing.com
<b>Correspondent Name:</b>	CLARK & ELBING LLP
<b>Address Line 1:</b>	101 FEDERAL STREET
<b>Address Line 2:</b>	15TH FLOOR
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	50671-003006
<b>NAME OF SUBMITTER:</b>	KRISTINA BIEKER-BRADY, PH.D.
<b>SIGNATURE:</b>	/Kristina Bieker-Brady, Ph.D./
<b>DATE SIGNED:</b>	03/10/2016
<b>Total Attachments: 2</b>	
source=Adagio - Confirmatory Assignment (23Feb2015) Signed#page1.tif	
source=Adagio - Confirmatory Assignment (23Feb2015) Signed#page2.tif	

## CONFIRMATORY ASSIGNMENT

For valuable consideration, we,

Full Name of Assignor	State of Incorporation	Business Address
Adagio Pharmaceuticals Ltd.	Canada	1302 Kestell Blvd. Oakville, Ontario L6H 0B9 Canada

hereby assign to


Full Name of Assignee	State of Incorporation	Business Address
Cynapsus Therapeutics, Inc.	Ontario, Canada	828 Richmond Street, W Toronto, Ontario M6J 1C9 Canada

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent signed by us, identified as:

Title of Application	Filing Date	Serial Number
SUBLINGUAL APOMORPHINE	June 12, 2009	61/186,445
SUBLINGUAL APOMORPHINE	June 11, 2010	12/813,820
SUBLINGUAL APOMORPHINE	June 11, 2010	PCT/US2010/038336
SUBLINGUAL APOMORPHINE	June 11, 2010	Australia Appl. No. AU2010259971
SUBLINGUAL APOMORPHINE	June 11, 2010	Brazil Appl. No. BR1120120002040
SUBLINGUAL APOMORPHINE	June 11, 2010	Canada Appl. No. CA2765291
SUBLINGUAL APOMORPHINE	June 11, 2010	China Appl. No. CN102480958
SUBLINGUAL APOMORPHINE	June 11, 2010	Hong Kong Appl. No.: 12112345.3
SUBLINGUAL APOMORPHINE	June 11, 2010	Europe Appl. No. EP10786915.8
SUBLINGUAL APOMORPHINE	June 11, 2010	Eurasia Appl. No. EA201270012
SUBLINGUAL APOMORPHINE	June 11, 2010	Indonesia Appl. No. WO0201104774
SUBLINGUAL APOMORPHINE	June 11, 2010	India Appl. No. 395/CHEN/2012
SUBLINGUAL APOMORPHINE	June 11, 2010	Israel Appl. No. IL216923
SUBLINGUAL APOMORPHINE	June 11, 2010	Japan Appl. No. JP2012-515185
SUBLINGUAL APOMORPHINE	June 11, 2010	Mexico Appl. No. MX2011013260
SUBLINGUAL APOMORPHINE	June 11, 2010	New Zealand Appl. No. NZ597237
SUBLINGUAL APOMORPHINE	June 11, 2010	South Africa Appl. No. ZA2011/09208
SUBLINGUAL APOMORPHINE	June 11, 2010	South Korea Appl. No. KR2012-7000835

This assignment includes said applications, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue

for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

  
Anthony John Giovinazzo  
Chairman & CEO  
Adagio Pharmaceuticals Ltd.

Feb 23 2015  
Date

Witness:

  
Signature

Feb 23 2015  
Date

Susan Thompson Printed name